+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768234
  • Report
  • 59 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Epizyme Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Italian Sarcoma Group
  • MORE
The global clinical trial report- “2019 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma). It presents in-depth analysis of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)

The research work is prepared through extensive and continuous research on Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) patients are identified
  • The report includes panorama of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Epizyme Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Italian Sarcoma Group
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials by Region
2.2.2 Average Enrollment of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Treatment, 2019

3. Region wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials
3.1 Asia Pacific Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials by Country
3.2 Europe Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials by Country
3.3 North America Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials by Country
3.4 Middle East and Africa Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials by Country
3.5 South and Central America Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials by Country

4. Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trial Trends
4.1 Start Year wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials
4.2 Phase wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials
4.3 Trial Status wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials
4.4 Trial Type wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials

5. Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Average Enrollment Trends
5.1 Average Enrollment in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Trials by Year
5.2 Average Enrollment in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Trials by Phase
5.3 Average Enrollment in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Trials by Status
5.4 Average Enrollment in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Trials by Type of Trial

6. Companies Participating in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials
6.1 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Trials by Sponsor Type
6.2 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Trials- Phase 1
7.2 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Trials- Phase 2
7.3 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Trials- Phase 3
7.4 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials and Enrolment
Figure 5: Europe - Country wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials and Enrolment
Figure 7: North America - Country wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials and Enrolment
Figure 9: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials by Phase
Figure 10: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials by Trial Status
Figure 11: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials by Type
Figure 12: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials by Sponsor Type
Figure 13: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials by Leading Sponsors
Figure 14: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Average Enrollment by Phase
Figure 15: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Average Enrollment by Trial Status
Figure 16: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Average Enrollment by Type
Figure 17: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)- Average Enrolment by Type of Sponsors
Figure 18: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials and Enrolment
Table 5: Europe - Country wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials and Enrolment
Table 7: North America - Country wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Average Enrollment by Phase
Table 15: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Average Enrollment by Trial Status
Table 16: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Average Enrollment by Type
Table 17: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)- Average Enrolment by Type of Sponsors
Table 18: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Epizyme Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Italian Sarcoma Group
  • Medpace Holdings Inc
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
Note: Product cover images may vary from those shown
Adroll
adroll